Baader Bank Aktiengesellschaft Takes $451,000 Position in Natera, Inc. (NASDAQ:NTRA)

Baader Bank Aktiengesellschaft bought a new position in Natera, Inc. (NASDAQ:NTRA - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 2,850 shares of the medical research company's stock, valued at approximately $451,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in NTRA. Chartwell Investment Partners LLC raised its position in shares of Natera by 37.9% during the 3rd quarter. Chartwell Investment Partners LLC now owns 41,302 shares of the medical research company's stock valued at $5,243,000 after buying an additional 11,362 shares in the last quarter. Cerity Partners LLC raised its position in Natera by 27.0% during the third quarter. Cerity Partners LLC now owns 86,144 shares of the medical research company's stock valued at $10,936,000 after purchasing an additional 18,316 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in shares of Natera in the 3rd quarter valued at approximately $385,000. Everence Capital Management Inc. purchased a new position in shares of Natera in the 4th quarter worth approximately $573,000. Finally, First Turn Management LLC bought a new position in shares of Natera during the 3rd quarter valued at approximately $19,760,000. 99.90% of the stock is owned by institutional investors.

Analyst Ratings Changes

NTRA has been the subject of several recent analyst reports. Leerink Partners lifted their price objective on shares of Natera from $140.00 to $150.00 and gave the stock an "outperform" rating in a research note on Thursday, October 17th. Piper Sandler upped their price target on shares of Natera from $150.00 to $200.00 and gave the company an "overweight" rating in a report on Monday, November 18th. TD Cowen raised their price objective on shares of Natera from $155.00 to $175.00 and gave the stock a "buy" rating in a research note on Wednesday, November 13th. Craig Hallum upped their target price on Natera from $121.00 to $157.00 and gave the company a "buy" rating in a research note on Wednesday, November 13th. Finally, Guggenheim raised their price target on Natera from $170.00 to $200.00 and gave the stock a "buy" rating in a research note on Friday, January 17th. One investment analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $165.88.

Insiders Place Their Bets

In related news, CEO Steven Leonard Chapman sold 4,728 shares of the company's stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $146.41, for a total value of $692,226.48. Following the sale, the chief executive officer now owns 185,034 shares in the company, valued at $27,090,827.94. This represents a 2.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Michael Burkes Brophy sold 4,335 shares of the stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $165.87, for a total transaction of $719,046.45. Following the completion of the transaction, the chief financial officer now owns 103,697 shares in the company, valued at approximately $17,200,221.39. This trade represents a 4.01 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 268,229 shares of company stock valued at $44,521,025. Insiders own 7.60% of the company's stock.

Natera Stock Down 0.2 %

NASDAQ NTRA traded down $0.41 on Monday, hitting $176.51. The stock had a trading volume of 931,632 shares, compared to its average volume of 1,385,712. Natera, Inc. has a 52-week low of $66.68 and a 52-week high of $183.00. The business's fifty day moving average price is $166.89 and its 200 day moving average price is $138.50. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. The stock has a market cap of $23.30 billion, a price-to-earnings ratio of -100.52 and a beta of 1.66.

Natera (NASDAQ:NTRA - Get Free Report) last announced its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.31. The company had revenue of $439.80 million for the quarter, compared to analyst estimates of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm's quarterly revenue was up 63.9% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.95) EPS. Equities research analysts anticipate that Natera, Inc. will post -1.56 earnings per share for the current year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.